TRAXENS
11.6.2019 09:02:08 CEST | Business Wire | Press release
Traxens, a company providing high-value data and services for the supply chain industry, today announces it has equipped the smart reefer containers of a leading Indoniesian NVOCC company, PT TKSolusindo, with its patented Traxens solution.
PT TKSolusindo is a major Non-Vessel Operating Common Carrier (NVOCC) in Indonesia, a country made up of 17,000 islands, where domestic container trades are essential in the daily life of inhabitants. The containers, delivered from the Taicang and Qingdao factories of China International Marine Containers (CIMC), were equipped with Traxens’ smart solutions in only a few days. These now bring PT TKSolusindo, and its clients, full visibility of shipped cargo in the controlled-atmosphere containers throughout all logistical legs of the journey.
Traxens’ solution addresses key challenges in the shipping industry faced by both asset owners and cargo owners. With the support of telematics, asset owners can control costs and develop more agile business problem solving, while cargo owners can easily keep track of their containers, bringing improved business processes and decision making capabilities. Reduced operational costs, improved supply chain efficiency, enhanced security and the opportunity to extend offerings to customers are amongst the key benefits gained through Traxens’ smart solutions. The whole shipping ecosystem, including ports, freight forwarders, insurance and financial institutions, can also benefit from the value-added data gathered by Traxens’ cutting-edge technology.
Traxens offers a comprehensive solution for the reefer industry, which comprises the company’s Reefer Fleet Management and Reefer Door-to-door Monitoring cloud-based applications via the Traxens-Hub, which collects data from Traxens-Box devices installed on containers.
“Traxens’s novel technology is a great addition to the services we provide to our customers, who are keen on staying informed about their cargo’s whereabouts and conditions at all times,” said Glenn Manoppo from PT TKSolusindo. “The reasonable and competitive pricing offered by Traxens were important in our decision when selecting the right partner for the digital transformation of our operations.”
“We are delighted that our reefer tracking technology was chosen by PT. TKSolusindo and we believe that our solution will support the company with the digital transformation of its shipping business,” said Jacques Delort, managing director of Traxens. “We look forward to further co-operations in Asia, a region where domestic and international shipping is crucial for economic success.”
Traxens counts major BCOs among its customers; it also partners with major shipping lines in providing bespoke tracking data for containers.
About PT Trans Kontainer Solusindo (TKSolusindo)
PT TKSolusindo is a subsidiary of an Integrated Cold Chain Solution Company of PT. Kiat Ananda Group, who became the first integrated services provider for refrigerated goods in Indonesia.
PT TKSolusindo specializes in domestic inter-island transport using reefer containers to reach other areas in Indonesia to distribute customers’s goods. The company was set up in 2014, and is now the largest NVOCC in Indonesia with major customers, including international brands such as Unilever, Pizza Hut, Starbucks, Yakult Probiotic, Kentucky Fried Chicken, Greenfield Diary, etc. and local brands such as Hypermart Retail, Hero Retail, Transmart Retail, Charoen Pokphand Indonesia etc. PT TKSolusindo manages more than 500 fleets, generators and trucking.
PT TKSolusindo will develop its international forwarding to support the group trading business in the future.
ABOUT TRAXENS
Traxens generates, collects, consolidates, enriches and transforms logistics asset data into actionable insight for its clients in the maritime, rail and supply chain industries.
The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multi-modal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers. Traxens’ IoT solution received the Frost & Sullivan’s Technology Leadership Award in 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005054/en/
Contact:
PRESS CONTACT : Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom